bluebird bio Inc
What Analysts Recommend for Celgene in 2017
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
XBI Rises in Contrast to a Flat Market
XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.
Do Analysts See Any Upside in BeiGene Stock?
Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data
On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.
BlueBird Bio Stock Jumps over 6% on May 17
BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.
XBI’s Moving Averages: The Massive Plummet Last Week
XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.
What Else Could Drive Gilead’s Long-Term Growth?
In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.
Biotech Stocks Hammered Badly Last Week after Clinton Comment
Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.
Will Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Commodities Fell, XBI Was the Weaker Biotech ETF
For the week ending December 11, most of the biotech stocks and ETFs were in the red. The SPDR S&P Biotech ETF (XBI) was the worst. It had a return of -6.5%.
Most Analysts Have Given bluebird bio Positive Ratings in March
Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Taking Stock of BeiGene’s Latest Performance
BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Editas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
A Look at Sage Therapeutics’ NMDA Receptor Portfolio
Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.
Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
How Analysts Rate Editas Medicine and Peers in August
Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
Celgene’s CAR T Cell Therapy Could Be Long-Term Growth Driver
In June 2018, Celgene (CELG) and Bluebird Bio (BLUE) presented updated results from the ongoing phase 1 CRB-401 trial of bb2121.
Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18
On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.
Intellia Therapeutics Stock Fell 9.8% on Monday
On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.
Versartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.
Why Omeros Stock Rose Last Week
On April 2, 2018, Omeros (OMER) stock opened at $11.12. It grew ~22% over the week to close at $13.58 on April 6.
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.
Exploring the Financial Performance of Akcea Therapeutics
In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.
Analysts’ Recommendations for Akcea and Its Peers in March
Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.
Cell Therapy Market Could Boost Celgene’s Long-Term Growth
With the acquisition of Juno Therapeutics, Celgene will benefit from all of Juno Therapeutics’ facilities related to cell therapy.
Behind Celgene’s Strategy in the Juno Therapeutics Acquisition
With the acquisition of Juno Therapeutics (JUNO), Celgene (CELG) will likely become an established cellular immunotherapy company.
Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.
A Look at Prospects for Genzyme, a Sanofi Company
Following its acquisition in 2011, Genzyme became a wholly owned subsidiary of Sanofi (SNY).
Naglazyme: One of the Costliest Drugs in the United States
The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.
IBB Leads Biotech ETFs with Rise of 3.1%
Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.
Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week
Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.
XBI’s Top Ten Small-Caps Outperform IBB’s Top Ten Small-Caps
Within the SPDR S&P Biotechnology ETF (XBI), ZIOPHARM Oncology (ZIOP) rose 18.55% for the week ending September 18.
XBI Stocks: 33% Are Trading above the 20-Day Moving Averages
XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.